Cite
HARVARD Citation
Kalakonda, N. et al. (2020). Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet. 7 (7), pp. e511-e522. [Online].